• 제목/요약/키워드: Severe Acute Respiratory Syndrome (SARS)

검색결과 181건 처리시간 0.039초

Newly Emerging Human Coronaviruses: Animal Models and Vaccine Research for SARS, MERS, and COVID-19

  • Pureum Lee;Doo-Jin Kim
    • IMMUNE NETWORK
    • /
    • 제20권4호
    • /
    • pp.28.1-28.25
    • /
    • 2020
  • The recent emergence of the novel coronavirus (CoV) or severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) poses a global threat to human health and economy. As of June 26, 2020, over 9.4 million cases of infection, including 482,730 deaths, had been confirmed across 216 countries. To combat a devastating virus pandemic, numerous studies on vaccine development are urgently being accelerated. In this review article, we take a brief look at the characteristics of SARS-CoV-2 in comparison to SARS and Middle East respiratory syndrome (MERS)-CoVs and discuss recent approaches to coronavirus disease-2019 (COVID-19) vaccine development.

A Comprehensive Study of SARS-CoV-2: From 2019-nCoV to COVID-19 Outbreak

  • Waris, Abdul;Ali, Muhammad;Khan, Atta Ullah;Ali, Asmat;Baset, Abdul
    • 한국미생물·생명공학회지
    • /
    • 제48권3호
    • /
    • pp.252-266
    • /
    • 2020
  • The coronavirus disease 2019 (COVID-19) is a highly contagious pneumonia that has spread throughout the world. It is caused by a novel, single stranded RNA virus called severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Genetic analysis revealed that, phylogenetically, the SARS-CoV-2 is related to severe acute respiratory syndrome-like viruses seen in bats. Because of this, bats are considered as a possible primary reservoir. The World Health Organization has declared the COVID-19 outbreak as a pandemic. As of May 27, 2020, more than 5,406,282 confirmed cases, and 343,562 confirmed deaths have been reported worldwide. Currently, there are no approved vaccines or antiviral drugs available against COVID-19. Newly developed vaccines are in the first stage of clinical trials, and it may take a few months to a few years for their commercialization. At present, remdesivir and chloroquine are the promising drugs for treating COVID-19 patients. In this review, we summarize the diversity, genetic variations, primary reservoirs, epidemiology, clinical manifestations, pathogenesis, diagnosis, treatment strategies, and future prospects with respect to controlling the spread of COVID-19.

Blood test results from simultaneous infection of other respiratory viruses in COVID-19 patients

  • In Soo, Rheem;Jung Min, Park;Seung Keun, Ham;Jae Kyung, Kim
    • International Journal of Advanced Culture Technology
    • /
    • 제10권4호
    • /
    • pp.316-321
    • /
    • 2022
  • Since 2019, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has spread rapidly, infecting millions of people worldwide. On March 11, 2020, the World Health Organization declared coronavirus disease (COVID-19) a pandemic owing to the worldwide spread of SARS-CoV-2, which created an unprecedented burden on the global healthcare system. In this context, there are increasing concerns regarding co-infections with other respiratory viruses, such as the influenza virus. In this study, clinical data of patients infected with SARS-CoV-2 and other respiratory viruses were compared with patients infected with SARS-CoV-2 alone. The hematology and blood biochemistry results of 178 patients infected with SARS-CoV-2 , who were tested on admission, were retrospectively reviewed. In patients with SARS-CoV-2 and adenovirus co-infection, C-reactive protein levels were elevated on admission, whereas lactate dehydrogenase (LDH), prothrombin time, international normalized ratio, activated partial thromboplastin clotting time, and bilirubin values were all within the normal range. Moreover, patients with SARS-CoV-2 and human bocavirus co-infection had low LDH and high bilirubin levels on admission. These findings reveal the clinical features of respiratory virus and SARS-CoV-2 co-infections and support the development of appropriate approaches for treating patients with SARS-CoV-2 and other respiratory virus co-infections.

Korean Red Ginseng, a regulator of NLRP3 inflammasome, in the COVID-19 pandemic

  • Jung, Eui-Man;Lee, Geun-Shik
    • Journal of Ginseng Research
    • /
    • 제46권3호
    • /
    • pp.331-336
    • /
    • 2022
  • Coronavirus disease 2019 (COVID-19) exhibits various symptoms, ranging from asymptomatic to severe pneumonia or death. The major features of patients in severe COVID-19 are the dysregulation of cytokine secretion, pneumonia, and acute lung injury. Consequently, it leads to acute respiratory distress syndrome, disseminated intravascular coagulation, multiple organ failure, and death. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative virus of COVID-19, influences nucleotide-binding oligomerization domain, leucine-rich repeat, and pyrin domain containing 3 (NLRP3), the sensor of inflammasomes, directly or indirectly, culminating in the assembly of NLRP3 inflammasome and activation of inflammatory caspases, which induce the inflammatory disruption in severe COVID-19. Accordingly, the target therapeutics for inflammasome has attracted attention as a treatment for COVID-19. Korean Red Ginseng (KRG) inhibits several inflammatory responses, including the NLRP3 inflammasome signaling. This review discusses the role of KRG in the treatment and prevention of COVID-19 based on its anti-NLRP3 inflammasome efficacy.

무세포 단백질 합성법을 이용한 활성형 SARS-3CL protease의 발현 (Expression of SARS-3CL Protease in a Cell-Free Protein Synthesis System)

  • 박선주;김용태
    • 생명과학회지
    • /
    • 제22권4호
    • /
    • pp.552-558
    • /
    • 2012
  • 사스(Severe acute respiratory syndrome, SARS)는 사람의 신종 폐렴인 중증 급성 호흡기 질환으로 신종 코로나바이러스, SARS-CoV에 의해 유발된다. 3CL protease는 SARS-CoV의 복제, 전사 및 단백질 합성을 조절하는 복제효소 복합단백질의 프로세싱에 결정적인 역할을 담당하는 중요한 효소이다. 따라서, 이 효소를 저해함으로써 SARS-CoV의 증식을 억제하고 사스의 증폭 및 확산을 막을 수 있다. SARS-3CL protease의 활성 저해물질의 탐색은 사스의 치료제 개발에 중요한 목표 중의 하나로 인식되고 있으며 이를 위해서는 활성형 SARS-3CL protease의 대량 생산이 필요하다. 본 연구에서는 활성형 SARS-3CL protease를 대량 생산하기 위하여 여러 가지 발현 벡터 및 단백질 발현 방법 등을 검토하였다. 그 결과, pET29a/3CLP 발현 벡터를 이용한 무세포 단백질 합성법이 SARS-3CL protease 생산에 최적 조건인 것으로 확인되었다. 또한 발현된 효소를 완전히 정제하여 그 특성을 분석한 결과, 본 효소는 무세포 단백질 합성계에서 전구체로 합성됨과 동시에 자가분해됨으로써 모든 단백질이 활성형인 성숙체 단백질로 전환되어 간단히 활성형 SARS-3CL protease 효소를 생산할 수 있음을 확인하였다.

COVID-19 Therapeutics: An Update on Effective Treatments Against Infection With SARS-CoV-2 Variants

  • Bill Thaddeus Padasas;Erica Espano;Sang-Hyun Kim;Youngcheon Song;Chong-Kil Lee;Jeong-Ki Kim
    • IMMUNE NETWORK
    • /
    • 제23권2호
    • /
    • pp.13.1-13.24
    • /
    • 2023
  • The coronavirus disease 2019 (COVID-19) pandemic is one of the most consequential global health crises in over a century. Since its discovery in 2019, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to mutate into different variants and sublineages, rendering previously potent treatments and vaccines ineffective. With significant strides in clinical and pharmaceutical research, different therapeutic strategies continue to be developed. The currently available treatments can be broadly classified based on their potential targets and molecular mechanisms. Antiviral agents function by disrupting different stages of SARS-CoV-2 infection, while immune-based treatments mainly act on the human inflammatory response responsible for disease severity. In this review, we discuss some of the current treatments for COVID-19, their mode of actions, and their efficacy against variants of concern. This review highlights the need to constantly evaluate COVID-19 treatment strategies to protect high risk populations and fill in the gaps left by vaccination.

False-Negative Results of Real-Time Reverse-Transcriptase Polymerase Chain Reaction for Severe Acute Respiratory Syndrome Coronavirus 2: Role of Deep-Learning-Based CT Diagnosis and Insights from Two Cases

  • Dasheng Li;Dawei Wang;Jianping Dong;Nana Wang;He Huang;Haiwang Xu;Chen Xia
    • Korean Journal of Radiology
    • /
    • 제21권4호
    • /
    • pp.505-508
    • /
    • 2020
  • The epidemic of 2019 novel coronavirus, later named as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is still gradually spreading worldwide. The nucleic acid test or genetic sequencing serves as the gold standard method for confirmation of infection, yet several recent studies have reported false-negative results of real-time reverse-transcriptase polymerase chain reaction (rRT-PCR). Here, we report two representative false-negative cases and discuss the supplementary role of clinical data with rRT-PCR, including laboratory examination results and computed tomography features. Coinfection with SARS-COV-2 and other viruses has been discussed as well.

사스 격리전담 병원 직원들의 사스에 대한 이해와 태도 조사 (SARS quarantining hospital employees's knowledge about SARS and attitude to SARS control)

  • 김우진;김영순;조희숙
    • Tuberculosis and Respiratory Diseases
    • /
    • 제55권4호
    • /
    • pp.361-369
    • /
    • 2003
  • 연구배경 : 국내에서는 2003년의 사스 유행기에 사스 방역에서 만족할 만한 성과를 거두었으나, 유행이 다시 시작되거나, 다른 새로운 점염병의 가능성이 있다. 사스 전담 병원 중의 한 병원에서 직원들을 대상으로 시행한 사스에 대한 설문조사를 통해 병원 직원들의 사스에 대한 이해정도와 태도에 미치는 영향을 파악하여 향후의 유사한 상황에 대비한 기초자료를 얻고자 하였다. 방 법 : 강원대학교병원의 전 직원을 대상으로 인구 사회학적 사항, 사스에 대한 지식 측정, 진료 참여 의향, 사스의 사회적 파장에 대한 의견, 정보 취득에 대한 내용으로 설문조사를 시행하였다. 사스에 대한 지식 정도와 사스에 대한 태도와의 관련성, 인구 사회학적 특성과 사스에 대한 태도와의 관련성에 대해 분석하였다. 결 과 : 280명 중 251명의 직원이 응답하였고, 사스지식에 대한 평균점수는 $72.0{\pm}13.7$이었다. 사스전담 팀참여에 대해 50.6%에서 참여하겠다고 응답하였다. 본원이 격리전담을 담당하는데 반대하는 의견은 23.1%였다. 사스 지식에 대한 점수와 사스 관리에 대한 태도사이에는 관련성이 없었다. 교육에 참여한 사람과 참여하지 않은 사람들 사이에 지식 점수의 차이는 없었다. 교육 시 알고싶은 내용으로 사스환자 관리요령과 개인별 예방법에 대한 것이 가장 많았다. 결 론 : 대중 매체를 통한 사스환자 관리요령과 개인별 예방법에 대한 정확한 국가적 정보제공이 중요할 것으로 사료되며, 사스에 대한 지식수준과 태도와의 관련성이 없었다.